Centrus Energy's shares fell sharply in pre-market activity, down about 3.9% to trade near $150, and pushed to an intraday 52-week low of $146.90. The decline continues a trend that began after the company's first-quarter 2026 report, which presented a mixed picture: management raised full-year revenue expectations and cited growth in its low-enriched uranium backlog, but investors focused on weaker profitability and missed top-line targets.
The company's reported earnings per share for the quarter were $0.45, compared with $1.60 in the same period a year earlier. Management attributed the year-over-year EPS drop largely to higher costs associated with advanced technology and capacity expansion initiatives. Those expense increases, combined with the revenue shortfall versus expectations, have weighed on investor confidence.
Analyst revisions have reinforced selling pressure. Several firms have cut price targets by double-digit amounts: for example, UBS lowered its target to $195 from $245, while Citi reduced its target to $225 from $292. Northland Securities trimmed its Q4 2026 EPS estimate for Centrus from $0.77 to $0.67, and a Needham analyst pared a price target even as the analyst retained a Buy rating. The string of downward adjustments has contributed to the stock's vulnerability.
Investors are also weighing valuation and insider activity. Centrus currently trades at a price-to-earnings ratio of 52.5x, markedly above both the U.S. Oil and Gas industry average of 13.8x and a peer average of 11.7x. That spread suggests meaningful valuation risk should market sentiment deteriorate further. Reports of insider selling add another dimension of caution for market participants evaluating near-term downside.
The broader market offered limited support on the day of the decline. The S&P 500 eased by about 0.3% and the NASDAQ fell approximately 1.0%, creating a risk-off backdrop that tended to pressure higher-multiple growth names. Within the nuclear-fuel group, some peers have held up better: companies such as Cameco and Uranium Energy Corp showed more resilient performance in 2026, indicating that much of Centrus's move appears to be company-specific rather than a sector-wide retrenchment.
Market data included in trading screens reflected volatility across related tickers. For example, Uranium Energy Corp (UEC) showed swings notable enough to be highlighted alongside Centrus (LEU) in intraday feeds. Centrus's stock has declined sharply over recent intervals: it is down more than 30% over the past 30 days and more than 40% year-to-date on a share price basis, and its share price has fallen to a level not seen in more than a year.
Putting the recent moves together, factors combining to push the stock lower include a lingering post-earnings hangover, multiple analyst target cuts, stretched valuation multiples and a weak session on the NASDAQ. Management's bookings in low-enriched uranium and a long-dated backlog provide arguments investors may cite for a longer-term constructive view, but the market's continuing pullback suggests that expectations are being reset amid near-term earnings volatility.
Summary
Centrus's stock has extended a post-earnings decline, hitting a fresh 52-week low after Q1 2026 results that balanced higher revenue guidance and backlog growth against substantially lower EPS and missed revenue expectations. Analyst target cuts, high relative valuation and a risk-off market environment have amplified selling pressure.
Key points
- Centrus shares dropped nearly 3.9% in pre-market trading to about $150 and reached an intraday 52-week low of $146.90.
- Q1 2026 EPS fell to $0.45 from $1.60 a year earlier, primarily due to higher costs tied to advanced technology and capacity expansion, despite an increased full-year revenue outlook and growing low-enriched uranium backlog.
- Several analysts cut price targets or earnings estimates, including UBS (to $195 from $245), Citi (to $225 from $292) and Northland Securities (Q4 2026 EPS lowered from $0.77 to $0.67).
Risks and uncertainties
- Valuation risk: Centrus trades at a P/E of 52.5x versus industry and peer averages of 13.8x and 11.7x respectively, exposing the stock to downside if sentiment weakens further.
- Near-term earnings volatility: Rising costs for advanced technology and capacity expansion have already driven a material drop in EPS, creating uncertainty around short-term profitability.
- Market risk: A risk-off session on major indexes (S&P 500 down ~0.3%, NASDAQ down ~1.0%) can disproportionately affect high-multiple growth names and exacerbate share declines.